Skip to content

Nafarelin studies: 87 papers with results

Page 2 of 2

Nafarelin has 224 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

  1. Preserving adult height potential in girls with idiopathic true precocious puberty.

    Kreiter M · The Journal of pediatrics · 1990

    Non-randomized trial · 3 results

  2. The rapid ovarian secretory response to pituitary stimulation by the gonadotropin-releasing hormone agonist nafarelin in sexual precocity.

    Rosenfield RL · The Journal of clinical endocrinology and metabolism · 1986

    Non-randomized trial · 10 results

  3. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis.

    Välimäki M · The Journal of clinical endocrinology and metabolism · 1989

    Non-randomized trial · 11 results

  4. Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis.

    Ylikorkala O · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 1990

    Non-randomized trial · 13 results

  5. The effect of nafarelin on human plasma adrenocorticotrophic hormone and cortisol concentrations.

    Overton CE · Human reproduction (Oxford, England) · 1993

    Non-randomized trial · 5 results

  6. Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas.

    Colombo P · European journal of endocrinology · 1994

    Non-randomized trial · 9 results

  7. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin).

    Schriock ED · Fertility and sterility · 1985

    Non-randomized trial · 11 results

  8. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men.

    Weber JP · American journal of hematology · 1991

    Non-randomized trial · 7 results

  9. Dose-related changes in LH bioactivity with intranasal GnRH agonist administration.

    Chiang RS · Contraception · 1985

    Non-randomized trial · 15 results

  10. Gonadotropin releasing hormone (GnRH) agonists in male contraception.

    Swerdloff RS · Medical biology · 1986

    Non-randomized trial · 4 results

  11. Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.

    Chan RL · Clinical pharmacology and therapeutics · 1988

    Non-randomized trial · 11 results

  12. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.

    Heiner JS · The Journal of clinical endocrinology and metabolism · 1995

    Non-randomized trial · 4 results

  13. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).

    Monroe SE · The Journal of clinical endocrinology and metabolism · 1986

    Non-randomized trial · 21 results

  14. Efficacy and safety of nafarelin in the treatment of endometriosis.

    Henzl MR · American journal of obstetrics and gynecology · 1990

    Non-randomized trial · 5 results

  15. Changes in vitamin D metabolism during natural and medical menopause.

    Hartwell D · The Journal of clinical endocrinology and metabolism · 1990

    Non-randomized trial · 8 results

  16. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study.

    El-Nemr A · European journal of obstetrics, gynecology, and reproductive biology · 2002

    Non-randomized trial · 18 results

  17. In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome.

    Cheung AP · Human reproduction (Oxford, England) · 2002

    Non-randomized trial · 2 results

  18. Effects of nafarelin on bone density.

    Jacobson JB · American journal of obstetrics and gynecology · 1990

    Non-randomized trial · 7 results

  19. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.

    Franssen AM · Fertility and sterility · 1992

    Observational study · 4 results

  20. Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat.

    Mizutani T · International journal of fertility and menopausal studies · 1995

    Animal study (in vivo) · rat · 3 results

  21. Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)6)]LHRH, in rhesus monkeys. I.

    Anik ST · Journal of pharmaceutical sciences · 1984

    Animal study (in vivo) · rhesus monkeys · 4 results

  22. Potentiation of the gonadotoxicity of Cytoxan in the dog by adjuvant treatment with a luteinizing hormone-releasing hormone agonist.

    Goodpasture JC · Cancer research · 1988

    Animal study (in vivo) · beagle dog · 9 results

  23. Reversibility of long-term effects of GnRH agonist administration on testicular histology and sperm production in the nonhuman primate.

    Weinbauer GF · Journal of andrology · 1987

    Animal study (in vivo) · macaca mulatta · 18 results

  24. Long-term reversible suppression of oestrus in bitches with nafarelin acetate, a potent LHRH agonist.

    McRae GI · Journal of reproduction and fertility · 1985

    Animal study (in vivo) · dog · 14 results

  25. Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.

    Sanders LM · Journal of pharmaceutical sciences · 1986

    Animal study (in vivo) · rat · 7 results

  26. Elevation of serum testosterone during chronic LHRH agonist treatment in the bull.

    Melson BE · Journal of animal science · 1986

    Animal study (in vivo) · bulls · 14 results

  27. Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist.

    Vickery BH · Journal of andrology · 1985

    Animal study (in vivo) · dog · 13 results

  28. Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.

    Chu NI · Drug metabolism and disposition: the biological fate of chemicals · 1985

    Animal study (in vivo) · rat and rhesus monkey · 7 results

  29. Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey.

    Chan RL · Drug metabolism and disposition: the biological fate of chemicals · 1985

    Animal study (in vivo) · rhesus monkey · 7 results

  30. Characterization of convective solvent flow during iontophoresis.

    Delgado-Charro MB · Pharmaceutical research · 1994

    Ex vivo tissue · mouse · 1 result

  31. False positive result for a peptide drug in the gene conversion assay with Saccharomyces cerevisiae strain D7.

    DePass LR · Fundamental and applied toxicology : official journal of the Society of Toxicology · 1991

    In vitro (cells) · saccharomyces cerevisiae · 6 results

  32. Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist.

    Chan RL · Biochemical and biophysical research communications · 1985

    In vitro (cell-free) · rhesus monkey and rat · 3 results

  33. Gonadotropin-releasing hormone agonist analog (nafarelin): a useful diagnostic agent for the distinction of constitutional growth delay from hypogonadotropic hypogonadism.

    Kletter GB · Journal of pediatric endocrinology & metabolism : JPEM · 1996

    Not a test of Nafarelin alone · 5 results

  34. Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis.

    Raiman J · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2004

    Not a test of Nafarelin alone · 4 results

  35. Stability of peptide drugs in the colon.

    Wang J · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2015

    Not a test of Nafarelin alone · 8 results

  36. Drug adsorption in human skin: a streaming potential study.

    Raiman J · Journal of pharmaceutical sciences · 2003

    Not a test of Nafarelin alone · 2 results

  37. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.

    Wang J · Molecular pharmaceutics · 2015

    Not a test of Nafarelin alone · 4 results

How PepBank reports evidence